Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Diluted Average) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Shares Outstanding (Diluted Average) for 16 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) fell 2.59% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 2.59% year-over-year, with the annual reading at $14.3 million for FY2025, 2.59% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $14.3 million at Anika Therapeutics, down from $14.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $14.8 million in Q3 2024, with the low at $218000.0 in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $12.2 million, with a median of $14.5 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 9459.6% in 2021, then dropped 3.0% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $233000.0 in 2021, then dropped by 3.0% to $226000.0 in 2022, then skyrocketed by 6384.96% to $14.7 million in 2023, then rose by 0.44% to $14.7 million in 2024, then decreased by 2.59% to $14.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $14.3 million, $14.4 million, and $14.3 million for Q4 2025, Q3 2025, and Q1 2025 respectively.